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This is a retrospective analysis of poorly-differentiated head and neck malignancies at University College Hospital,
Ibadan.
Eighty-six poorly-differentiated neoplasms were categorized as carcinomas, sarcomas, lymphomas or
neuroendocrine cancers with a panel of 7 antibodies (cytokeratin AE1/AE3, vimentin, desmin, myogenin, leukocyte
common antigen and neuron-specific enolase). Immunohistochemical and original hematoxylin-eosin diagnoses
were contrasted.
The male: female ratio was 2.5:1, with mean age of 38.9 years. Nasopharynx, nose and maxillofacial bones were the
most common locations. Immunohistochemistry confirmed 54.8% of carcinomas, 70.6% of sarcomas and 80% of
lymphomas.
Hematoxylin-eosin was able to distinguish between sarcoma and lymphoma but differentiation between a
carcinoma and neuroendocrine lesion was poor. Further studies are required to maximize the role of
immunohistochemistry as an ancillary diagnostic tool in the West African sub-region.
Introduction
Histological examination plays a central role in diagnosis,
classification, grading and staging of malignancy. Difficul-
ties arise from the subjective nature of histological analy-
sis that are influenced by the practitioner’s experience,
bias and training. With poorly-differentiated neoplasms,
inter- and intra-observer variability can be high [1].
Immunohistochemistry has greatly assisted in the identi-
fication of tumors that cannot be accurately identified
using routine histopathological procedures [2]. In one
study of more than 100 anaplastic tumors, the hematoxy-
lin-eosin diagnosis of carcinoma or lymphoma was
revised in approximately 50% of cases following immuno-
histochemical analysis [3].
In some undifferentiated tumors, subtle features of
epithelial versus mesenchymal differentiation can often
be appreciated, which assist the immunohistochemical
approach to these tumors. Some tumors, however, may
not fit into either of these two categories because of their
overlapping histological features [4]. Nevertheless, mak-
ing the correct histopathological diagnosis is essential in
deciding the appropriate therapy [5,6].
The immunohistochemical evaluation of undifferen-
tiated tumors should first aim at a broad lineage determi-
nation of the neoplasia. Based on the result of the
screening panel, a more detailed or specific panel should
then be applied to further sub classify the tumor or to
confirm a particular diagnosis [4]. The thrust of this study
is to evaluate the accuracy of histopathological diagnosis
in the broad lineage determination of undifferentiated/
poorly-differentiated neoplasms of the head and neck.
Methodology
1192 head and neck malignancies (oral and nasal cav-
ities, paranasal sinuses, oropharynx, nasopharynx, hypo-
pharynx, larynx, trachea, ear and salivary glands) were
retrieved from the archives of the Pathology and Oral
Pathology departments of the University College
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poorly-differentiated and undifferentiated neoplasms
including anaplastic (undifferentiated) or poorly-differ-
entiated carcinomas, anaplastic large cell lymphomas,
pleomorphic sarcomas, malignant fibrous histiocytoma,
esthesioneuroblastoma and spindle cell sarcomas were
selected. Cases where the original paraffin block could
not be obtained were excluded from analysis. Only 86 of
the 142 undifferentiated and poorly-differentiated head
and neck malignancies diagnosed during the study per-
iod satisfied the inclusion criteria.
Freshly prepared sections from each case were stained
with hematoxylin-eosin (H&E) and a panel of antibodies
to leukocyte common antigen (CD45), cytokeratin AE1/
AE3, vimentin, desmin, myogenin and neuron-specific
enolase (NSE) using the specifications of the manufac-
turer (Dako Cytomation, USA).
The sections for immunohistochemistry were de-par-
affinized, hydrated and then rinsed in Phosphate Buf-
fered Solution (PBS). They were immersed in heat
induced epitope retrieval citrate buffer diluted to 1:10
with distilled water and incubated at 90°C for 1 hour.
They were then placed in fresh citrate, cooled in water
for 20 minutes and then rinsed in PBS. Positive controls
(skin for cytokeratin AE1 or AE3, tonsils for CD45;
neural tissue for Neuron-specific enolase; skeletal mus-
cle for Myogenin and Vimentin; and smooth muscle for
desmin) and negative controls were employed for each
antibody. 3% hydrogen peroxide was added to each sec-
tion for 10 minutes and the sections were rinsed in 0.1%
PBS. The specimens were incubated for an hour with
40-130 μl of appropriately diluted Dako mouse primary
antibody, followed by incubation with undiluted labeled
polymer Horse Radish Peroxidase conjugated antimouse
secondary antibody for 30 minutes. One ml of Diamino-
benzidene solution was added to cover the specimen,
followed by incubation in a humidity chamber for 15
minutes. The sections were then immersed in aqueous
hematoxylin and rinsed in distilled water. The tissue
was then dehydrated and subsequently rinsed with
xylene. DPX (Distyrene, Plasticizer and Xylene) mount-
ing fluid was then applied and a cover slip placed.
All the seven antibodies used in the panel for one spe-
cimen were reviewed sequentially and the pattern and
intensity of staining was observed and scored as: nega-
tive (0), weakly positive (+1), moderately positive (+2)
and strongly positive (+3) [7]. The slides were reviewed
without reference to initial histology diagnosis to elimi-
nate bias. The final immunohistochemical findings were
then correlated with the H&E stained slides in order to
arrive at a final diagnosis.
The data was analyzed using version 16 of the Statisti-
cal Package for Social Sciences (SPSS16). Qualitative
data were compared using chi-square statistics.
Quantitative data were summarized using mean, stan-
dard deviation and confidence interval and compared
using student t- and/or one-way analysis of variance
test. The level of significance was set at p < 0.05. Sensi-
tivity and specificity were calculated using immunohisto-
chemistry as the gold standard to which the original
H&E diagnosis was compared. The positive predictive
value, negative predictive value, accuracy and degree of
agreement were also determined. For degree of agreement,
Kappa value >0.75 = excellent agreement, 0.4-0.75 =
fair to good agreement and <0.4 = moderate to poor
agreement [8].
Results
The cases comprised 62 (72.1%) males and 24 (27.9%)
females. The mean age was 38.9 (SD ± 15.9) with peak
occurrence between 25-44 years. The nasopharynx
(47.7%), nose (12.8%) and maxillofacial bones (12.8%)
were the most common locations.
The original hematoxylin-eosin diagnoses are shown in
figure 1. These diagnoses were confirmed by immunohis-
tochemistry in 34 (54.8%) of the 62 carcinomas, 12 (70.6%)
of the 17 sarcomas, four (80%) of the 5 lymphomas and
one of the 2 neuroendocrine malignancies (Table 1).
Table 2 summarizes the clinical profile of the 33 cases
in which there was discordance between the original
H&E diagnosis and final diagnosis. Some of these dis-
cordant diagnoses are also depicted in figures 2, 3, 4, 5,
6 and 7. Sarcomas, neuroendocrine carcinomas and lym-
phomas were most often misdiagnosed as carcinomas.
There was no obvious correlation between age, gender
or site distribution, as compared to diagnosis.
The sensitivity of histology was highest for carcinomas
(97.1%) and least for neuroendocrine lesions (14.2%).
Specificity of histology was highest for neuroendocrine
lesions (98.6%) and lymphomas (98.4%) and least for
carcinomas (47.7%). The positive predictive values of
histology was highest for sarcomas and lymphomas
(80% each), while the negative predictive value was high-
est for carcinomas (95.4%). Accuracy of histology was
highest for the neuroendocrine tumors (91.1%). The
level of agreement between histology and immunohisto-
chemistry, given by the kappa values, was highest for
sarcomas (54%) (Table 3).
Discussion
In the present study, the original histological diagnosis
of 62 lesions was carcinoma, but only 34 (54.8%) were
confirmed by immunohistochemistry. This proportion is
higher than the 27.9% confirmation rate of carcinomas
in a study by Bianchini et al in Italy [9]. Lesions that
were confused with carcinomas included 8 (12.9%) sar-
comas, 8 (12.9%) lymphomas, 6 (9.7%) neuroendocrine
tumors and 1 carcinosarcoma. Gatter [10] also reported
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thought to be anaplastic carcinomas were revised as
lymphomas by immunohistochemistry. This demon-
strates the value of immunohistochemistry in distin-
guishing between anaplastic carcinomas and malignant
lymphomas of the head and neck, as the latter is much
more amenable to treatment than the former. This
study thus corroborates other studies which suggest that
immunohistochemical technique has a role in the defini-
tion of undifferentiated tumors.
Eighty percent of lymphomas diagnosed by histology
in this study were confirmed by immunohistochemistry
and this is comparable to the 66% reported confirmation
of lymphomas in another study [3].
After the immunohistochemical analysis, almost 10%
of the lesions thought to be undifferentiated carcinomas
were revised to neuroendocrine carcinomas. More than
60% of these revised lesions were found either in the
nose or nasopharynx and occurred more commonly in
males (66.7%). Histopathological differentiation of undif-
ferentiated carcinoma from neuroendocrine carcinoma
is challenging and is significantly aided by immunohisto-
chemistry [11].
The present study had inconclusive diagnosis by
immunohistochemistry in 8.1% of cases, Bianchini et al
reported 18.6% and Gatter reported 6.7% inconclusive
results. This could be due to technique differences, dif-
ferent antigen retrieval methods or the absence of the
antigen suspected. Use of inappropriate antibodies may
also be responsible for absence of immunoreactivity. In
addition, some poorly-differentiated tumors might
require other techniques such as electron microscopy
and molecular studies before an accurate diagnosis can
be achieved [12,13].
In this study, histology, to a reasonable extent is able
to determine if a sarcoma or lymphoma is present or if
Figure 1 Histological diagnoses of 86 poorly differentiated/undifferentiated head and neck malignancies.
Table 1 Comparison of histology diagnosis with immunohistochemical assessment
IMMUNOHISTOCHEMISTRY DIAGNOSIS
HISTOLOGY DIAGNOSIS CA SARC LYMPH NE-CA CA-SARC INCONCLUSIVE TOTAL
CA 34 8 8 6 1 5 62
SARC 11 2 2 0 0 2 1 7
LYMPH 01 4 0 0 0 5
NE-CA 01 0 1 0 0 2
TOTAL 35 22 14 7 1 7 86
KEY: CA- carcinoma, SARC- sarcoma, LYMPH- lymphoma, NE-CA- neuroendocrine carcinoma.
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of certainty, determine if a carcinoma or a neuroendo-
crine tumor is present, although it can exclude them
fairly accurately. The high number of carcinomas seen
in this study therefore suggests an over-diagnosis of car-
cinomas by histology. For correct management to be
instituted for any malignant lesion it must be diagnosed
accurately. In this study the diagnostic accuracy of his-
tology for carcinomas is 69.6%. This means that almost
70% of the time, histology will diagnose carcinomas
accurately. The diagnostic accuracy for sarcomas, lym-
phomas and neuroendocrine tumors is 83.5%, 86% and
91.1% respectively. Therefore further ancillary tests will
be needed to resolve diagnostic doubts.
The level of agreement in this study between morpho-
logical classification by histology and immunohisto-
chemical assessment was fair for sarcomas (kappa =
0.54), moderate for carcinomas and lymphomas (kappa
= 0.42), and poor for neuroendocrine tumors (kappa =
0.18). However, a larger sample of neuroendocrine
tumors will be required before any affirmative deduc-
tions can be made about them.
Undifferentiated carcinomas were the most prevalent
group in this study constituting 64% of the undifferen-
tiated malignancies and 7.6% of all head and neck malig-
nancies. A study by Gatter et al [10] in the United
Kingdom recorded poorly-differentiated lymphomas
(44.2%) as the most prevalent undifferentiated tumors.
Bianchini et al [9] however reported in their study that
the most prevalent cell pattern for poorly-differentiated
tumors was the round cell pattern (51%). They only
grouped these lesions into their histogenetic lineage
after immunohistochemistry and not before [9]. In prac-
tice however a protocol should be developed, guiding









Carcinoma Neuroendocrine carcinoma 25-44 Male Lymph node
Carcinoma Neuroendocrine carcinoma 45-64 Female Nose
Carcinoma Neuroendocrine carcinoma 45-64 Male Nasopharynx
Carcinoma Neuroendocrine carcinoma 25-44 Female Nose
Carcinoma Neuroendocrine carcinoma 15-24 Male Palate
Carcinoma Neuroendocrine carcinoma ≥65 Male Nasopharynx
Carcinoma Sarcoma 25-44 Male Face/scalp
Carcinoma Sarcoma 15-24 Male Nasopharynx
Carcinoma Sarcoma 45-64 Male Lymph node
Carcinoma Sarcoma 25-44 Male Nasopharynx
Carcinoma Sarcoma 25-44 Male Nose
Carcinoma Sarcoma 15-24 Male Nose
Carcinoma Sarcoma 45-64 Male Nasopharynx
Carcinoma Sarcoma 45-64 Female Maxillofacial
bone
Carcinoma Lymphoma ≥65 Male Nasopharynx
Carcinoma Lymphoma 45-64 Male Nasopharynx
Carcinoma Lymphoma 25-44 Male Oropharynx
Carcinoma Lymphoma —— Male Oropharynx
Carcinoma Lymphoma 15-24 Male Maxillofacial
bone
Carcinoma Lymphoma 45-64 Male Nose
Carcinoma Lymphoma 25-44 Female Nasopharynx
Carcinoma Lymphoma 45-64 Female Nasopharynx
Carcinoma Carcinosarcoma 45-64 Male Nasopharynx
Sarcoma Carcinoma 45-64 Female Face/scalp
Sarcoma Lymphoma 15-24 Male Maxillofacial
bone
Sarcoma Lymphoma 25-44 Male Maxillofacial
bone
Lymphoma Sarcoma 25-44 Male Nose
Neuroendocrine carcinoma Sarcoma 45-64 Male Nasopharynx
Adisa et al. Head & Neck Oncology 2010, 2:33
http://www.headandneckoncology.org/content/2/1/33
Page 4 of 8Figure 2 Photomicrographs showing the Immunohistochemical profile of a neuroendocrine carcinoma. The haematoxylin and eosin
(H&E) section shows highly pleomorphic cells with nuclei vessiculation and prominent nucleoli disposed in islands. Moderate immunopositivity
of neurone specific enolase (NSE) for epithelioid-like cells is noted. Epithelial markers (AE1 and AE3) are strongly positive and there is a non-
specific staining pattern of epithelial cells and lymphocytes with vimentin (VIM). The tumour is negative for desmin (DES) and leukocyte
common antigen (LCA). All immunohistochemical sections were counterstained with hematoxylin. (X400)
Figure 3 Photomicrographs showing the immunohistochemical profile of a rhabdomyosarcoma including the haematoxylin and eosin
(H&E) slide which displays sheets of pleomorphic and polymorphic cells which have hyperchromatic nuclei. There is strong
immunopositivity for myogenin (MYO), moderate positivity for vimentin (VIM) and equivocal staining with desmin (DES) and neurone specific
enolase (NSE). There is also negativity for epithelial markers (AE1 and AE3) and leukocyte common antigen (LCA). All immunohistochemical
sections were counterstained with hematoxylin. (X400)
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Page 5 of 8Figure 5 Photomicrographs are showing the immunohistochemical profile of a lymphoma including the haematoxylin and eosin
(H&E) slide which shows some small blue round and spindle cells with indistinct cytoplasm. There is immunopositivity for leukocyte
common antigen (LCA). All of the other immunohistochemical markers are negative. All immunohistochemical sections were counterstained
with hematoxylin. (X400).
Figure 4 Photomicrographs show the immunohistochemical profile of a non Hodgkin’s lymphoma including the haematoxylin and
eosin (H&E) slide that shows a highly cellular lesion with minimal supporting loose connective tissue stroma. There is strong
immunopositivity of the malignant lymphoid cells for leukocyte common antigen (LCA). All of the other immunohistochemical markers (AE1,
AE3, myogenin (MYO), vimentin (VIM), desmin (DES), and neuron specific enolase (NSE) are negative. All immunohistochemical sections were
counterstained with hematoxylin. (X400).
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Page 6 of 8Figure 6 Photomicrographs show the immunohistochemical profile of a leiomyosarcoma including the haematoxylin and eosin (H&E)
slide. The islands of spindle cells with wavy nuclei show strong immunopositivity for desmin (DES). All of the other markers are negative, with
fibrous connective tissue staining for vimentin (VIM). All immunohistochemical sections were counterstained with hematoxylin. (X400).
Figure 7 Photomicrographs show the immunohistochemical profile of a squamous cell carcinoma including the haematoxylin and
eosin (H&E) slide which show a follicular arrangement of small round hyperchromatic cells. There is strong immunopositivity for
cytokeratin AE1 and moderate positivity for AE3. All of the other immunohistochemical markers are negative. All immunohistochemical sections
were counterstained with hematoxylin. (X400).
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phology to reduce ‘wastage’ of antibodies.
Conclusion
In this study, test of sensitivity and specificity show that
histology is able to determine the presence or absence
of a sarcoma or lymphoma to a good extent but confir-
mation of a carcinoma or neuroendocrine lesion is poor,
although it is able to exclude them fairly accurately.
This study has also shown that the use of antibodies in
immunohistochemistry greatly assist in the identification
of tumors which cannot be accurately identified using
routine histopathological procedures.
More detailed studies for specific pathological condi-
tions need to be carried out in order to maximize
immunohistochemistry as an ancillary diagnostic tool
and expand its versatility in Nigeria and the West Afri-
can sub-region.
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Table 3 Sensitivity and specificity of histology
Carcinomas Sarcomas Lymphomas Neuroendocrine carcinomas
Sensitivity 0.971 0.545 0.285 0.142
Specificity 0.477 0.947 0.984 0.986
PPV 0.596 0.800 0.800 0.500
NPV 0.954 0.843 0.864 0.922
Accuracy 0.696 0.835 0.860 0.911
Kappa statistics value 0.42 0.54 0.42 0.18
PPV - positive predictive value, NPV - negative predictive value.
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